KRAS and neoplasm: The immune responses of TCR-engineered Jurkat cells or primary T cells were detected using IL-2 or IFN-γ ELISPOT or ELISA assays after co-culturing with target cells loaded with peptides or tumor cells intrinsically expressing KRAS mutants.